Catalog Products » LFNG Antibody, mAb, Rabbit
Manual
Manual
COAs

LFNG Antibody, mAb, Rabbit

Glycosyltransferase that initiates the elongation of O-linked fucose residues attached to EGF-like repeats in the extracellular domain of Notch molecules. Modulates NOTCH1 activity by modifying O-fucose residues at specific EGF-like domains resulting in inhibition of NOTCH1 activation by JAG1 and enhancement of NOTCH1 activation by DLL1 via an increase in its binding to DLL1.
$210.00
A04183-50

Ask us a question
Overview
Specificity This product is specific to LFNG
Host Species Rabbit
Immunogen A synthesized peptide derived from human LFNG
Species Reactivity Human; Mouse; Rat
Conjugate Unconjugated
Back

Applications
Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.
Application Recommended Usage
Western Blot 1:1000-1:2000
Immunocytochemistry/Immunofluorescence (ICC/IF) 1:50-1:200
Back

Properties
Form Liquid
Storage Buffer Supplied in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.
Storage Instructions Store at -20°C. This product is stable for 1 year upon receipt, when handled and stored as instructed.
Purification Affinity-chromatography
Isotype Rabbit IgG
Clonality Monoclonal
Back

LFNG Antibody, MAb, Rabbit

Western blot analysis of Lunatic Fringe expression in HeLa cell lysate. »

<
>

Background
Target Background Glycosyltransferase that initiates the elongation of O-linked fucose residues attached to EGF-like repeats in the extracellular domain of Notch molecules. Modulates NOTCH1 activity by modifying O-fucose residues at specific EGF-like domains resulting in inhibition of NOTCH1 activation by JAG1 and enhancement of NOTCH1 activation by DLL1 via an increase in its binding to DLL1.
Synonyms SCDO3;
Back

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.